ETANA STRENGTHENS BIOPHARMACEUTICAL COOPERATION WITH CANSINOBIO

Jakarta, 18 October 2023 – PT Etana Biotechnologies Indonesia (Etana), a biopharmaceutical company from Indonesia, has entered into a strategic collaboration with CanSino Biologics Inc (CanSinoBIO) at the Indonesia-People's Republic of China (PRC) Business Forum that was held at China World Hotel, Beijing, PRC, on Monday, October 16, 2023. This forum was held to commemorate the 10th anniversary of the Belt and Road Initiative (BRI), as well as to encourage joint development between the two countries.

In this forum, Etana and CanSinoBIO, a leading innovative vaccine company, have signed a cooperation document which is the only one in the biopharmaceutical field between China and Indonesia, witnessed by President Joko Widodo. The signing of this document marks an important milestone in strengthening strategic cooperation in the field of research and development of vaccines and biological products that will provide real benefits for both countries.

Nathan Tirtana, President Director of Etana, with Dr. Xuefeng Yu, Chairman and CEO of CanSinoBIO, has agreed to collaborate in the research and development of technology for inhaled tuberculosis vaccine and tetravalent meningitis vaccine.

Nathan Tirtana said that the main objective of this collaboration is to jointly face the threat of disease effectively, create innovation in the biopharmaceutical field, and provide health benefits to the community.

"This collaboration is proof of our commitment to supporting global health development and deepening cooperation between China and Indonesia in building a high-quality Belt and Road. "We are confident that with the technology transfer process we can carry out research on vaccines and biological products that are high quality, affordable and innovative," said Nathan.

Previously, Etana had also signed a memorandum of understanding on vaccine evaluation platform with Tsinghua University and CanSinoBIO on the island of Bali. The signing of this memorandum of understanding deepens strategic cooperation between Indonesia and China in the field of vaccines, by using the latest technology to produce innovative and high-quality vaccines for the Southeast Asian region.

Etana at a glance

Established in 2014, Etana is an Indonesian biopharmaceutical company that researches, manufactures and markets biological therapies for the Southeast Asian market. With a mission to serve patients by providing high quality, affordable, and innovative therapies, the company has built state-of-the-art local production facility that meet international and Indonesian FDA standards. The facility is able to produce biological therapy with halal certification from the Indonesian Ulema Council (MUI). Etana aspires to become a leading biopharmaceutical company in the ASEAN region through aggressive expansion in production capacity and product development, with a primary focus on oncology and vaccine products.

Etana is led by a local management team who come from various international and domestic educational backgrounds and have strong experience in the biopharmaceutical industry, and are supported by a team of international investors and leading biopharmaceutical companies. Etana aims to provide innovative yet affordable therapies through local production, to support Indonesian government programs and larger market demands. Etana is currently a leading biotech company in Indonesia committed to the research and manufacture of monoclonal antibodies, mRNAs and other biological platforms. For more information on Etana, visit: www.id.etanabiotech.com